Cost-effectiveness analysis of domestic 13-valent pneumococcal conjugate vaccine for children under 5 years of age in mainland China

doi:10.1080/21645515.2020.1870396

LZUFE-KMS > 校领导

	Cost-effectiveness analysis of domestic 13-valent pneumococcal conjugate vaccine for children under 5 years of age in mainland China
	Wang, Caixia 1,2; Su, Li 2; Mu, Qiuling 3; Gu, Xueyan 2; Wang, Xuejun4 ; Guo, Xuxia 1
	2021-02
发表期刊	HUMAN VACCINES & IMMUNOTHERAPEUTICS
卷号	17 期号:7 页码:2241-2248
摘要	Background: The first Chinese domestic 13-valent pneumococcal conjugate vaccine (WoAnxin (R), PCV-13) is available for children aged 2 months to 5 years and is more economical than import vaccine with equal safety and immunogenicity. However, the cost-effectiveness of this new PCV-13 for children Methods: In the present study, we developed a Markov model under societal perspective to evaluate the incremental cost-effectiveness ratios (ICERs) of five birth cohorts of 100,000 Chinese infants across four alternative vaccination programs:1) no vaccination; 2) vaccinate 4 doses of new PCV-13 for children aged 2 to 6 months; 3) vaccinate 3 doses of new PCV-13 for children aged 7 to 11 months; 4) vaccinate 2 doses of new PCV-13 for children aged 12 to 23 months; 5) vaccinate 1 dose of new PCV-13 for children aged 2 to 5 years. We conducted one-way and probability sensitivity analysis to determine the uncertainty of the model findings. Results: We found that with awillingness-to-pay (WTP) threshold of three-times Chinese per-capita gross domestic product (GDP) all vaccination programs were cost-effective compared to no vaccination and children aged 2 to 5 years received 1 dose of new PCV-13 would incur the lowest additional cost of US$2417 per quality-adjusted-life-years (QALYs) compare with other vaccination programs ($15394/QALYs for 4 doses program, $9292/QALYs for 3 doses program, $4445/QALYs for 2 doses program). Conclusions: According to our results, China should give priority to incorporating new PCV-13 into its national immunization program.
关键词	Cost-effectiveness analysis Chinese domestic 13-valent pneumococcal conjugate vaccine pneumococcal disease infants Streptococcus pneumoniae
DOI	10.1080/21645515.2020.1870396
收录类别	SCOPUS ; SCIE
ISSN	2164-5515
语种	英语
WOS研究方向	Biotechnology & Applied Microbiology ; Immunology
WOS类目	Biotechnology & Applied Microbiology ; Immunology
WOS记录号	WOS:000617588800001
出版者	TAYLOR & FRANCIS INC
原始文献类型	Article
EISSN	2164-554X
引用统计	被引频次：10[WOS] [WOS记录] [WOS相关记录]
文献类型	期刊论文
条目标识符	http://ir.lzufe.edu.cn/handle/39EH0E1M/21301
专题	校领导
通讯作者	Guo, Xuxia
作者单位	1.Gansu Prov Ctr Dis Prevent & Control, Inst Hlth Educ, Lanzhou 730000, Peoples R China; 2.Lanzhou Univ, Sch Publ Hlth, Lanzhou, Peoples R China; 3.Gansu Prov Hlth Vocat Coll, Clin Nursing Coll, Lanzhou, Peoples R China; 4.Lanzhou Univ Finance & Econ, Sch Business Adm, Lanzhou, Peoples R China
推荐引用方式 GB/T 7714	Wang, Caixia,Su, Li,Mu, Qiuling,et al. Cost-effectiveness analysis of domestic 13-valent pneumococcal conjugate vaccine for children under 5 years of age in mainland China[J]. HUMAN VACCINES & IMMUNOTHERAPEUTICS,2021,17(7):2241-2248.
APA	Wang, Caixia,Su, Li,Mu, Qiuling,Gu, Xueyan,Wang, Xuejun,&Guo, Xuxia.(2021).Cost-effectiveness analysis of domestic 13-valent pneumococcal conjugate vaccine for children under 5 years of age in mainland China.HUMAN VACCINES & IMMUNOTHERAPEUTICS,17(7),2241-2248.
MLA	Wang, Caixia,et al."Cost-effectiveness analysis of domestic 13-valent pneumococcal conjugate vaccine for children under 5 years of age in mainland China".HUMAN VACCINES & IMMUNOTHERAPEUTICS 17.7(2021):2241-2248.